EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PBPK modeling of recombinant factor IX Fc fusion protein ( rFIXFc ) and rFIX to characterize the binding to type 4 collagen in the extravascular space

Michael E Cloesmeijer iD, Erik Sjögren iD, Sjoerd F Koopman iD, Peter J Lenting iD, Marjon H Cnossen iD, Ron A A Mathôt iD, OPTI‐CLOT study group and SYMPHONY consortium

CPT: Pharmacometrics & Systems Pharmacology · 2024-10 · 13 (10) · 1630-1640

DOI: 10.1002/psp4.13159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 16.09.2024. Verfasst von Michael E Cloesmeijer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy-Clinical Pharmacology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Collagen Type IV, Recombinant Fusion Proteins, Factor IX, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with severe and sometimes moderate hemophilia B are prophylactically treated with factor IX concentrates to prevent bleeding. For some time now, various extended terminal half‐life (EHL) recombinant factor IX concentrates are available allowing less frequent administration during prophylaxis in comparison to standard half‐life recombinant FIX (rFIX). Especially, recombinant FIX‐Fc fusion protein (rFIXFc; Alprolix®) exhibits a rapid distribution phase, potentially due to binding to type IV collagen (Col4) in the extravascular space. Studies suggest that the presence of extravascular rFIXFc is protective against bleeding as without measurable FIX activity in plasma, and no extra bleeding seems to occur. The physiologically based pharmacokinetic (PBPK) model for rFIXFc which we describe in this study, is able to accurately predict the observed concentration‐time profiles of rFIXFc in plasma and is able to quantify the binding of rFIXFc to Col4 in the extravascular space after an intravenous dose of 50 IU/kg rFIXFc in a male population. Our model predicts that the total AUC of rFIXFc bound to Col4 in the extravascular space is approximately 19 times higher compared to the AUC of rFIXFc in plasma. This suggests that rFIXFc present in the extravascular compartment may play an important role in achieving hemostasis after rFIXFc administration. Further studies on extravascular distribution of rFIXFc and the distribution profile of other EHL‐FIX concentrates are needed to evaluate the predictions of our PBPK model and to investigate its clinical relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Collagen Type IVRecombinant Fusion ProteinsFactor IXImmunoglobulin Fc FragmentsHemophilia BHumansMaleModels, BiologicalProtein BindingHalf-Life

Substanzen

Collagen Type IVRecombinant Fusion ProteinsFactor IXImmunoglobulin Fc Fragmentsfactor IX Fc fusion protein

Autor:innen und Institutionen

  • Department of Hospital Pharmacy-Clinical Pharmacology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
  • Pharmetheus, Uppsala, Sweden.
  • Laboratory for Hemostasis, Inflammation & Thrombosis, Unité Mixed de Recherche (UMR)-1176, Institut National de la Santé et de la Recherche Médicale (Inserm), Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Department of Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.

ORCID-Profile: Michael E Cloesmeijer, Erik Sjögren, Sjoerd F Koopman, Peter J Lenting, Marjon H Cnossen, Ron A A Mathôt

Zitieren

APA

Cloesmeijer, M. E., Sjögren, E., Koopman, S. F., Lenting, P. J., Cnossen, M. H., Mathôt, R. A. A., & OPTI‐CLOT study group and SYMPHONY consortium (2024). PBPK modeling of recombinant factor IX Fc fusion protein ( rFIXFc ) and rFIX to characterize the binding to type 4 collagen in the extravascular space. CPT: Pharmacometrics & Systems Pharmacology, 13(10), 1630-1640. https://doi.org/10.1002/psp4.13159

Vancouver

Cloesmeijer ME, Sjögren E, Koopman SF, Lenting PJ, Cnossen MH, Mathôt RAA, et al. PBPK modeling of recombinant factor IX Fc fusion protein ( rFIXFc ) and rFIX to characterize the binding to type 4 collagen in the extravascular space. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(10):1630-1640. doi:10.1002/psp4.13159

BibTeX
@article{Cloesmeijer2024,
  author = {Cloesmeijer, Michael E and Sjögren, Erik and Koopman, Sjoerd F and Lenting, Peter J and Cnossen, Marjon H and Mathôt, Ron A A and OPTI‐CLOT study group and SYMPHONY consortium, OPTI‐CLOT study group and SYMPHONY consortium},
  title = {PBPK modeling of recombinant factor IX Fc fusion protein ( rFIXFc ) and rFIX to characterize the binding to type 4 collagen in the extravascular space},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {1630--1640},
  doi = {10.1002/psp4.13159}
}
Kostenlos starten →